Skeletal Dysplasia Account Manager; Central Region

Remote - USA

Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on.

In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life‑changing medicines for patients with unmet needs as fast as humanly possible.

Together we define white space, push boundaries, and empower people to solve problems. If you’re someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we’ll ask “why not?” and help reengineer the future of biopharma. At Bridge Bio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

The Skeletal Dysplasia Account Manager is a high‑impact, community‑focused role central to Bridge Bio’s commercial success. This individual will drive the launch of Infigratinib—a first‑in‑class therapy for achondroplasia—bringing deep clinical acumen, urgency, and a passion for partnering with providers and families.

Central Region – Multiple territories covering the following areas:
Chicago, Minneapolis, Indianapolis, Cincinnati, Detroit, Kansas City

• Develop and execute a dynamic territory business plan targeting geneticists, pediatric endocrinologists, orthopedic specialists, pediatricians, and multidisciplinary skeletal dysplasia clinic teams to meet and exceed sales goals.
• Demonstrate deep expertise in Infigratinib, achondroplasia, and the broader skeletal dysplasia landscape; engage HCPs in clinically relevant, compliant discussions.
• Use sales and target data to identify growth opportunities and address territory challenges proactively.
• Anticipate potential business challenges, adjust priorities as needed, demonstrate flexibility, and develop solutions to address challenges.
• Partner compliantly with Field Medical Directors, Field Reimbursement Managers, Family Account Managers, and the HUB to maximize customer and family satisfaction.
• Build and maintain relationships with KOLs in partnership with Marketing and Medical Affairs to expand advocacy for Infigratinib and Bridge Bio.
• Operate with an “One Bridge” mindset—collaborating across the organization to execute company initiatives and represent Bridge Bio with integrity.
• Maintain an exceptional level of proficiency in selling skills, clinical, market and product knowledge and the business environment of the territory.
• Ensure all activities comply with applicable regulations, company policies, and pharmaceutical guidelines.

Competitive Mindset

• Business Acumen & Results Orientation: Balance priorities and leverage available resources to drive results; apply strong analytical skills to surface opportunities in the skeletal dysplasia market.
• Resilience & Confidence: Hunter’s mentality with the resilience to identify and support families living with achondroplasia across geographically dispersed centers of care.

Customer Focus

• Build Trusting Relationships: Trusted advisor who anticipates and addresses the needs of skeletal dysplasia providers, genetic counselors, and families.
• Clinical Acumen & Learning Agility: Continuously deepen clinical knowledge of achondroplasia; sought out as a condition and product expert by HCPs and their teams.

Key Account Success

• Influence with Impact: Engage multidisciplinary care teams—from geneticists to orthopedic specialists to community advocacy groups—with credible, complex influence strategies.
• Teamwork and Coordination: Prioritize the community and business while collaborating closely with the Regional Sales Director and cross‑functional partners to execute a successful launch.

• 8–10 years in pharmaceutical or biotech; 4+ years in rare disease, genetic disease, or skeletal dysplasia required. Achondroplasia or pediatric rare…